What Caused Natera Shares to Drop?
Yahoo Finance ·
Shares of Natera tumbled 8.5% on Monday, November 2, 2026, while the S&P 500 slipped 0.5%. Although the company released no official corporate statements, every single peer in its sector moved lower. The broader market experienced a soft session, with the Nasdaq Composite dropping 1.1% as investors braced for upcoming Apple earnings, midterm elections, and Friday jobs data. Natera remains a high-growth firm yet lacks operating profitability, posting 37.8% revenue growth over the twelve months leading to June 30, 2026, alongside an operating loss of $290 million. During its August 6 earnings call, management revised its full-year 2026 revenue guidance to a range of $2.85 billion and $2.91 billion. On November 2, Myriad Genetics retreated 7.9% and Guardant Health fell 4.5%, dragging down the peer group further than the broader healthcare index. These pullbacks lowered Natera from its 52-week closing high of $436.00 reached on October 29, 2026, ahead of its upcoming third-quarter earnings report scheduled for later in November 2026.
AI 시장 분석
On November 2, 2026, Natera (NTRA) shares plummeted by 8.5% without any special corporate disclosures, significantly outperforming the S&P 500's 0.5% decline. On this day, not only Natera but also industry peers such as Myriad Genetics (-7.9%) and Guardant Health (-4.5%) fell together. Market-wide caution was at play ahead of Apple's earnings release, the midterm elections, and the employment data release.
하락 영향
- Biotechnology — Investment sentiment contracted as Natera and peer biotech and diagnostic companies fell simultaneously, and profit-taking orders for high-valuation growth stocks were issued.
DYAX 전담 분석
Natera recorded a high revenue growth of 37.8% over the past 12 months, but as a growth stock generating an operating loss of $290 million, it reacted sensitively to macroeconomic uncertainties. With a PSR of 20.1x, which is higher than the S&P 500 (3.3x), it is analyzed that profit-taking selling was concentrated ahead of major events.
The upcoming Q3 earnings release in November and the trend in Signatera test volume are key indicators that will determine the direction of the stock price. It may rebound once macroeconomic risks are resolved, but if signs of a slowdown in growth are captured, there is a risk of further correction.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 63% · Bearish (Short) 37%
369 participants
Related News
- Stock Market Today: Dow Slides 300 Points On Election Day; Apple, Palantir Dive On Earnings
- SK Hynix Discloses 9.1% Stake in Penguin Solutions via SEC Filing
- Optimistic Outlook for AMD Driven by Accelerating Server CPU Demand
- Vestel and Anadolu Offload TOGG Stakes for $412M
- Analyzing Investor Response to Alphabet's Euro Bond Issuance for AI Infrastructure
- Apple Sheds Roughly $140 Billion After Hours as New CEO Flags Memory Costs
